Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
PolyPeptide Group AG
PPGNPolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V. Address: Neuhofstrasse 24, Baar, Switzerland, 6340
Analytics
Preço Alvo de Wall Street
28.33 CHFRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave PPGN
Análise de Dividendos PPGN
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
123 %Histórico de Dividendos PPGN
Avaliação de ações PPGN
Relatório PPGN
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |